IL-17 inhibitors Cosentyx and Taltz will struggle to achieved preferred brand position in US formularies unless a separate category is created for this group of drugs.
By Astrid Kurniawan, Analyst
16 September 2016
I am an analyst for the market access and strategy team at Datamonitor Healthcare, where my aim is to provide an analysi...
Read full bio
Newly launched interleukin (IL) inhibitors face the formidable challenge of gaining preferred brand formulary position in the US market share against established tumor necrosis factor (TNF)-alpha inhibitors due to the latter group’s approvals and leading positions in the larger inflammatory markets. Contracts for these classes of medications fall under the broad category of inflammatory diseases, of which rheumatoid arthritis is the largest market segment. Despite having established superior or comparable efficacy to TNF-alpha inhibitors, payers have more leverage in contracting for large-volume products in the same category, such as Enbrel (etanercept; Amgen/Pfizer/Takeda) or Humira (adalimumab; AbbVie/Eisai), instead of drugs with fewer approvals in the inflammatory market. Manufacturers of Cosentyx (secukinumab; Novartis), Stelara (ustekinumab; Johnson & Johnson), and Taltz (ixekizumab; Eli Lilly) need to intensify their discussions with payers regarding the creation of a separate category for psoriasis drugs in order to overcome this obstacle.
Get your free demo of Datamonitor Healthcare tody. Simply fill out the form to the right >>>